Sigve Andersen
Stillingsbeskrivelse
Mitt forskningsområde er hovedsaklig translasjonell kreftforskning på lungekreft. Jeg er også involvert i forskning innen andre tumorgrupper som prostata, kolorektalkreft og innen fagfeltet palliasjon. Min undervisning er hovedsaklig orientert rundt palliasjon, men også generell kreft. Jeg er også fast medlem i eksamenskommisjonen for avsluttende eksamen.
Marianne Jensen Hjermstad,
Aleksandra Pirnat,
Nina Kathrine Aass,
Sigve Andersen,
Guro Lindviksmoen Astrup,
Olav Dajani
m.fl.:
PALLiative care in ONcology (PALLiON): A cluster-randomised trial investigating the effect of palliative care on the use of anticancer treatment at the end of life
Hallgeir Selven,
Lill-Tove Rasmussen Busund,
Sigve Andersen,
Mona Irene Pedersen,
Ana Paola Lombardi,
Thomas Karsten Kilvær
:
High Expression of IRS-1, RUNX3 and SMAD4 Are Positive Prognostic Factors in Stage I–III Colon Cancer
Marie Grøn Sælen,
Line Veronika Hjelle,
Erling Johan Aarsæther,
Tore Knutsen,
Sigve Andersen,
Anne Gry Bentzen
m.fl.:
Patient-reported outcomes after curative treatment for prostate cancer with prostatectomy, primary radiotherapy or salvage radiotherapy
Line Veronika Hjelle,
Marie Grøn Sælen,
Erling Johan Aarsæther,
Tore Knutsen,
Sigve Andersen,
Anne Gry Bentzen
m.fl.:
The Longitudinal Course of Prospectively Recorded Patient-reported Outcomes in Prostate Cancer Patients Treated with Surgery and Salvage Radiotherapy
Erna-Elise Paulsen,
Sigve Andersen,
Mehrdad Rakaee,
Mona Irene Pedersen,
Ana Paola Lombardi,
Mette Pøhl
m.fl.:
Impact of microvessel patterns and immune status in NSCLC: a non-angiogenic vasculature is an independent negative prognostic factor in lung adenocarcinoma
Mehrdad Rakaee,
Sigve Andersen,
K. Giannikou,
Erna-Elise Paulsen,
Thomas Karsten Kilvær,
Lill-Tove Rasmussen Busund
m.fl.:
Machine learning-based immune phenotypes correlate with STK11/KEAP1 co-mutations and prognosis in resectable NSCLC: a sub-study of the TNM-I trial
Therese Haugdahl Nøst,
Anne Heidi Skogholt,
Ilona Halva Urbarova,
Robin Mjelle,
Erna-Elise Paulsen,
Tom Dønnem
m.fl.:
Increased levels of microRNA-320 in blood serum and plasma is associated with imminent and advanced lung cancer
Mehrdad Rakaee,
Elio Adib,
Biagio Ricciuti,
Lynette M. Sholl Sholl,
Weiwei Shi,
Joao V. Alessi
m.fl.:
Association of machine learning-based assessment of tumor-infiltrating lymphocytes on standard histologic images with outcomes of immunotherapy in patients with NSCLC
JAMA Oncology 17. november 2022 DOI
Hallgeir Selven,
Sigve Andersen,
Mona Irene Pedersen,
Ana Paola Lombardi,
Lill-Tove Rasmussen Busund,
Thomas Karsten Kilvær
:
High expression of miR-17-5p and miR-20a-5p predicts favorable disease-specific survival in stage I-III colon cancer
Sissel Gyrid Freim Wahl,
Yan Dai Hong,
Elisabeth Fritzke Emdal,
Thomas Berg,
Tarje Onsøien Halvorsen,
Anine Larsen Ottestad
m.fl.:
The prognostic effect of KRAS mutations in non-small cell lung carcinoma revisited: A norwegian multicentre study
Maria Jenvin Støen,
Sigve Andersen,
Mehrdad Rakaee,
Mona I. Pedersen,
Lise Martine Ingebriktsen,
Tom Dønnem
m.fl.:
Overexpression of mir-20a-5p in tumor epithelium is an independent negative prognostic indicator in prostate cancer—a multi-institutional study
Mehrdad Rakaee,
Thomas Karsten Kilvær,
Simin Jamaly,
Thomas Berg,
Erna-Elise Paulsen,
Marte Berglund
m.fl.:
Tertiary lymphoid structure score: a promising approach to refine the TNM staging in resected non-small cell lung cancer
British Journal of Cancer 2021 DOI
Maria Jenvin Støen,
Sigve Andersen,
Mehrdad Rakaee,
Mona Irene Pedersen,
Lise Martine Ingebriktsen,
Roy M. Bremnes
m.fl.:
High expression of miR-17-5p in tumor epithelium is a predictor for poor prognosis for prostate cancer patients
Hallgeir Selven,
Lill-Tove Rasmussen Busund,
Sigve Andersen,
Roy M. Bremnes,
Thomas Karsten Kilvær
:
High expression of microRNA‑126 relates to favorable prognosis for colon cancer patients
Håkon Andre Ramberg,
Elin Richardsen,
Gustavo Antonio De Souza,
Mehrdad Rakaee,
Maria Stensland,
Peder Rustøen Braadland
m.fl.:
Proteomic analyses identify major vault protein as a prognostic biomarker for fatal prostate cancer
Thomas Karsten Kilvær,
Erna-Elise Paulsen,
Sigve Andersen,
Mehrdad Rakaee,
Roy M. Bremnes,
Lill-Tove Rasmussen Busund
m.fl.:
Digitally quantified CD8+ cells: the best candidate marker for an immune cell score in non-small cell lung cancer?
Elin Richardsen,
Sigve Andersen,
Christian Melbø-Jørgensen,
Mehrdad Rakaee,
Nora Ness,
Samer Al-Saad
m.fl.:
MicroRNA 141 is associated to outcome and aggressive tumor characteristics in prostate cancer
Mehrdad Rakaee,
Lill-Tove Busund,
Simin Jamaly,
Erna-Elise Paulsen,
Elin Richardsen,
Sigve Andersen
m.fl.:
Prognostic Value of Macrophage Phenotypes in Resectable Non–Small Cell Lung Cancer Assessed by Multiplex Immunohistochemistry
Elin Richardsen,
Sigve Andersen,
Samer Al-Saad,
Mehrdad Rakaee,
Yngve Nordby,
Mona Irene Pedersen
m.fl.:
Low expression of miR-424-3p is highly correlated with clinical failure in prostate cancer
Sigurd Hald,
Mehrdad Rakaee,
Inigo Zubiavrre Martinez,
Elin Richardsen,
Samer Al-Saad,
Erna Elise Paulsen
m.fl.:
LAG-3 in Non-Small-cell Lung Cancer: Expression in Primary Tumors and Metastatic Lymph Nodes Is Associated With Improved Survival
Clinical Lung Cancer 2018 DOI
Kaja Konstanse Skjefstad,
Charles Johannessen,
Thea K.W. Grindstad,
Thomas Karsten Kilvær,
Erna Elise Paulsen,
Mona Irene Pedersen
m.fl.:
A gender specific improved survival related to stromal miR-143 and miR-145 expression in non-small cell lung cancer
Mehrdad Rakaee,
Thomas Karsten Kilvær,
Stig Manfred Dalen,
Elin Richardsen,
Erna Elise Paulsen,
Sigurd Hald
m.fl.:
Evaluation of tumor-infiltrating lymphocytes using routine H&E slides predicts patient survival in resected non-small cell lung cancer
Human Pathology 2018 DOI
Thea K.W. Grindstad,
Elin Richardsen,
Sigve Andersen,
Kaja Konstanse Skjefstad,
Mehrdad Rakaee,
Tom Dønnem
m.fl.:
Progesterone receptors in prostate cancer: Progesterone receptor B is the isoform associated with disease progression
Yury Kiselev,
Sigve Andersen,
Charles Johannessen,
Bjørn Fjukstad,
Karina Standahl Olsen,
Helge Stenvold
m.fl.:
Transcription factor PAX6 as a novel prognostic factor and putative tumour suppressor in non-small cell lung cancer
Yngve Nordby,
Elin Richardsen,
Nora Ness,
Tom Dønnem,
Hitendra R.H. Patel,
Lill-Tove Busund
m.fl.:
High miR-205 expression in normal epithelium is associated with biochemical failure - An argument for epithelial crosstalk in prostate cancer?
Elin Richardsen,
Sigve Andersen,
Samer Al-Saad,
Mehrdad Rakaee,
Yngve Nordby,
Mona Irene Pedersen
m.fl.:
Evaluation of the proliferation marker Ki-67 in a large prostatectomy cohort
Yngve Nordby,
Elin Richardsen,
Mehrdad Rakaee,
Nora Ness,
Tom Dønnem,
Hitendra R.H. Patel
m.fl.:
High expression of PDGFR-β in prostate cancer stroma is independently associated with clinical and biochemical prostate cancer recurrence
Samer Al-Saad,
Elin Richardsen,
Thomas Karsten Kilvær,
Tom Dønnem,
Sigve Andersen,
Mehrdad Rakaee
m.fl.:
The impact of MET, IGF-1, IGF1R expression and EGFR mutations on survival of patients with non-small-cell lung cancer
Erna-Elise Paulsen,
Thomas Karsten Kilvær,
Mehrdad Rakaee,
Elin Richardsen,
Sigurd Hald,
Sigve Andersen
m.fl.:
CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases
falah jabar,
Sigve Andersen,
Erna-Elise Paulsen,
Masoud Tafavvoghi,
Elin Helmine Richardsen,
Sissel Gyrid Freim Wahl
m.fl.:
Integrating Artificial intelligence (AI)-based lymphocytic infiltration assessment in early-stage NSCLC: A sub-study of the TNM-I trial
2024
Øyvind Rolland,
Sigve Andersen,
Stian Aagnes,
Åslaug Helland
:
Stian har livstruende lungekreft: – Jeg er beviset på at forskning nytter
08. juni 2023
Tonje Lundeby,
Nina Kathrine Aass,
Sigve Andersen,
Sjur Bjørnar Hanssen,
Marianne Jensen Hjermstad,
Stein Kaasa
m.fl.:
Family carers' experiences with brain metastases: A longitudinal study
2023
Marianne Jensen Hjermstad,
Aleksandra Pirnat,
Nina Kathrine Aass,
Sigve Andersen,
Guro Lindviksmoen Astrup,
Olav Dajani
m.fl.:
1592MO Anticancer therapy at the end-of-life: A cluster-randomized trial
Annals of Oncology 2023 DOI
Mehrdad Rakaee,
Elio Adib,
Biagio Ricciuti,
Lynette M. Sholl,
Joao V.Alessi,
Alessio Cortellini
m.fl.:
Digital quantification of lymphocytic infiltration on routine H&E images and immunotherapy response in non-small cell lung cancer
2022
Mehrdad Rakaee,
Elio Adib,
Biagio Ricciuti,
Lynette M. Sholl,
Weiwei Shi,
Joao V Alessi
m.fl.:
Computational pathology by Artificial Intelligence (AI) on quantifying the lymphocytic infiltration predicts the immunotherapy response in NSCLC
2022
Therese Haugdahl Nøst,
Ilona Halva Urbarova,
Anne Heidi Skogholt,
Robin Mjelle,
Erna Elise Paulsen,
Tom Dønnem
m.fl.:
Increased levels of mRNAs and miRNAs associated with imminent and advanced lung cancer
2022
Mehrdad Rakaee,
Elio Adib,
Biagio Ricciuti,
Lynette M. Sholl,
Weiwei Shi,
Joao V.Alessi
m.fl.:
Artificial intelligence in digital pathology approach identifies the predictive impact of tertiary lymphoid structures with immune-checkpoints therapy in NSCLC
2022
Marianne Jensen Hjermstad,
Nina Kathrine Aass,
Sigve Andersen,
Cinzia Brunelli,
Olav Dajani,
Herish Ahmed
m.fl.:
PALLiON - PALLiative care Integrated in ONcology: Study protocol for a Norwegian national cluster-randomized control trial with a complex intervention of early integration of palliative care
Bente Ervik,
Sigve Andersen,
Helge Skirbekk,
Tom Dønnem
:
Evaluating a centralised cancer support centre in the remote region of Northern Norway
Stein Kaasa,
Marianne Bahus,
Sigve Andersen,
Peder Broen,
Helge Farsund,
Anne Marie Flovik
m.fl.:
De er døende. Gi dem lindring
Dagbladet 2020
Marianne Bahus,
Sigve Andersen,
Peder Broen,
Helge Farsund,
Anne Marie Flovik,
Søren Vincent Hagerup
m.fl.:
Organisering av det palliative tilbudet
Faglig begrunnet eller et udemokratisk politisk spill?
Fædrelandsvennen 24. august 2020
Bente Ervik,
Tone Nordøy,
Sigve Andersen
:
Fruktene av "Lindring i nord"
Sigve Andersen,
Tom Dønnem
:
Krafttak mot kreft
14. mars 2019
Tom Dønnem,
Sigve Andersen
:
Jakter på kroppens krigerceller
18. september 2019
Tom Dønnem,
Sigve Andersen
:
Jakter på kroppens krigerceller
05. september 2019
Kristin Benjaminsen Borch,
Sigve Andersen,
Line Merethe Oldervoll,
Sveinung Berntsen
:
Hva vet onkologer om fysisk aktivitet og kreft?
2019
Sigve Andersen
:
Folkemøte om prostatakreft
2019
Jan Henrik Rosland,
Olav Hevrøy,
Birthe Lie Hauge,
Anne Kari Knudsen,
Peder Broen,
Sigve Andersen
:
Nasjonalt handlingsprogram for palliasjon i kreftomsorgen
2019
Kaja Konstanse Skjefstad,
Thea K.W. Grindstad,
Mehrdad Rakaee,
Elin Richardsen,
Tom Dønnem,
Thomas Karsten Kilvær
m.fl.:
Corrigendum to "Prognostic relevance of estrogen receptor α, β and aromatase expression in non-small cell lung cancer" [Steroids 113 (2016) 5-13]
Steroids 2018 DOI
Sigve Andersen
:
Langt kommet Prostatakreft – hva gjør vi nå?
2017
De 50 siste resultatene fra Cristin vises på siden. Se alle arbeider i Cristin her →
Forskningsinteresser
Translasjonell kreftforskning innen lunge og prostatakreft
Lindrende behandling